China “resolutely opposes” a probe by the United States International Trade Commission into complaints of price-fixing by Chinese steelmakers, the Ministry of Commerce said yesterday.
The country is “strongly dissatisfied” with the decision and will encourage its firms to legally defend their interests.
Trade remedy measures recently taken by the US are “protectionism,” and will disrupt trade rather than solve US steel industry problems, the ministry said in a statement.
The current steel industry woes are global challenges that require coordinated efforts to solve, it said.
The USITC said on Thursday that it will investigate a complaint by US Steel Corp of Pittsburgh, which claimed Chinese steelmakers and distributors conspired to fix prices, stole trade secrets and misrepresented the origin of their exports to the US.
In its complaint under section 337 of the main US tariff law, the company is seeking to bar nearly all imports from China’s largest steelmakers.
The investigation will involve 40 Chinese steel producers and distribution subsidiaries, including Baosteel, Hebei Iron and Steel, Wuhan Iron and Steel, and Anshan Iron and Steel.
Baosteel Group yesterday accused the US of breaking World Trade Organization rules and vowed to appeal against the investigation.
Full Content: China Daily
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas